

A Small Shared Epitope–Mimetic Compound Potently Accelerates Osteoclast-Mediated Bone Damage in Autoimmune Arthritis

This information is current as of September 6, 2013.

Jiaqi Fu, Song Ling, Ying Liu, Jianyi Yang, Shirly Naveh, Margaret Hannah, Chaim Gilon, Yang Zhang and Joseph Holoshitz

J Immunol 2013; 191:2096-2103; Prepublished online 24 July 2013;
doi: 10.4049/jimmunol.1203231
<http://www.jimmunol.org/content/191/5/2096>

-
- References** This article **cites 35 articles**, 13 of which you can access for free at:
<http://www.jimmunol.org/content/191/5/2096.full#ref-list-1>
- Subscriptions** Information about subscribing to *The Journal of Immunology* is online at:
<http://jimmunol.org/subscriptions>
- Permissions** Submit copyright permission requests at:
<http://www.aai.org/ji/copyright.html>
- Email Alerts** Receive free email-alerts when new articles cite this article. Sign up at:
<http://jimmunol.org/cgi/alerts/etoc>

A Small Shared Epitope–Mimetic Compound Potently Accelerates Osteoclast-Mediated Bone Damage in Autoimmune Arthritis

Jiaqi Fu,^{*,1} Song Ling,^{*,1} Ying Liu,^{*} Jianyi Yang,[†] Shirly Naveh,[‡] Margaret Hannah,^{*} Chaim Gilon,[‡] Yang Zhang,[†] and Joseph Holoshitz^{*}

We have recently proposed that the shared epitope (SE) may contribute to rheumatoid arthritis pathogenesis by acting as a ligand that activates proarthritogenic signal transduction events. To examine this hypothesis, in this study we characterized a novel small SE-mimetic compound, *c*(HS4-4), containing the SE primary sequence motif QKRAA, which was synthesized using a backbone cyclization method. The SE-mimetic *c*(HS4-4) compound interacted strongly with the SE receptor calreticulin, potently activated NO and reactive oxygen species production, and markedly facilitated osteoclast differentiation and function in vitro. The pro-osteoclastogenic potency of *c*(HS4-4) was 100,000- to 1,000,000-fold higher than the potency of a recently described linear SE peptidic ligand. When administered in vivo at nanogram doses, *c*(HS4-4) enhanced Th17 expansion, and in mice with collagen-induced arthritis it facilitated disease onset, increased disease incidence and severity, enhanced osteoclast abundance in synovial tissues and osteoclastogenic propensities of bone marrow–derived cells, and augmented bone destruction. In conclusion, *c*(HS4-4), a highly potent small SE-mimetic compound enhances bone damage and disease severity in inflammatory arthritis. These findings support the hypothesis that the SE acts as a signal transduction ligand that activates a CRT-mediated proarthritogenic pathway. *The Journal of Immunology*, 2013, 191: 2096–2103.

It has long been observed that individuals carrying *HLA-DRB1* alleles that code a particular 5 aa sequence motif in position 70–74 of the HLA-DR β -chain are at significantly higher risk of developing severe rheumatoid arthritis (RA) (1). The mechanism by which this motif, commonly called shared epitope (SE), affects disease susceptibility and severity has been enigmatic since its identification more than two decades ago (2–5). We have recently demonstrated that the SE acts as a signal transduction ligand that interacts with cell surface calreticulin (CRT), an established innate immune system receptor (6). In other studies, we have identified the SE binding site on CRT (7) and determined the spatial requirements for optimal receptor binding and signal transduction potency during SE–CRT interaction (7, 8).

Engagement of cell surface CRT by the SE ligand activates signal transduction events that result in lineage-dependent functional consequences. For example, in CD8⁺CD11c⁺ dendritic cells,

the SE inhibits the activity of indoleamine 2, 3-deoxygenase, an enzyme known to play an important role in regulatory T cell activation. In CD8[−]CD11c⁺ dendritic cells, the SE triggers production of IL-6 and IL-23, cytokines known to be involved in activation and expansion of IL-17–producing T (Th17) cells. The end result of these two complementing effects is a potent SE-activated Th17 polarization, both in vitro and in vivo (9).

More recently, using transgenic mice expressing SE-positive human HLA-DR molecules, as well as 15-mer linear synthetic peptides expressing the SE sequence motif, we have demonstrated that the SE facilitates osteoclast (OC) differentiation and functional activation. Moreover, when administered in vivo, the 15-mer SE peptidic ligand enhanced erosive bone damage in collagen-induced arthritis (CIA) in mice (10).

Beyond shedding light on RA pathogenesis, the findings with linear peptides expressing allele-specific sequences suggest that in addition to their putative role in Ag presentation, HLA-coded molecules can contribute to the pathogenesis of autoimmune diseases through allele-specific ligands that activate aberrant signaling events with resultant disease (10). Given the disease specificity and well-defined structure–function properties of such ligands, one cannot avoid wondering whether these properties could be exploited for structure-based rational design of new therapeutic strategies.

The utility of short linear peptides has two important limitations. First, such peptides lack metabolic stability owing to rapid degradation in biologic milieus. Second, they are usually in fast equilibrium among many conformations in solution with no single restricted conformation, which results in suboptimal target engagement. To overcome these limitations, we have recently synthesized and screened a library of backbone-cyclized 5-mer peptides, all carrying the primary sequence QKRAA (the most common SE motif, coded by the RA-associated allele *HLA-DRB1*04:01*). We identified one particular compound with high potency that could

^{*}Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI 48109; [†]Department of Computational Medicine and Bioinformatics, University of Michigan School of Medicine, Ann Arbor, MI 48109; and [‡]Institute of Chemistry, Hebrew University of Jerusalem, 91904 Jerusalem, Israel

¹J.F. and S.L. contributed equally to this work.

Received for publication November 26, 2012. Accepted for publication June 21, 2013.

This work was supported by National Institutes of Health Grants GM088560, AR059085, and AR048310 (to J.H.), and GM083107 and GM084222 (to Y.Z.).

Address correspondence and reprint requests to Prof. Joseph Holoshitz, University of Michigan, 5520D MSRB1, 1150 West Medical Center Drive, Ann Arbor, MI 48109-5680. E-mail address: jholo@umich.edu

Abbreviations used in this article: BM, bone marrow; BW, body weight; CIA, collagen-induced arthritis; CII, collagen type II; CRT, calreticulin; DLN, draining lymph node; micro-CT, micro-computerized tomography; OC, osteoclast; RA, rheumatoid arthritis; RANKL, receptor activator for NF- κ B ligand; ROS, reactive oxygen species; SE, shared epitope; SPR, surface plasmon resonance; TRAP, tartrate-resistant acid phosphatase.

Copyright © 2013 by The American Association of Immunologists, Inc. 0022-1767/13/\$16.00

activate NO signaling in low nanomolar concentrations (~50,000-fold more active on a molar basis than the linear 65–79*0401 synthetic peptide). This low-molecular-mass (969-Da) compound, designated *c*(HS4-4), was remarkably stable toward trypsin/chymotrypsin degradation, whereas the linear peptidic SE ligand completely degraded within 30 min (11).

Given the signaling potency and biologic stability of *c*(HS4-4), we have undertaken to study its arthritogenic effect. In this article, we report that compound *c*(HS4-4) showed high affinity to the SE-binding receptor CRT and activated *in vitro* pro-osteoclastogenesis at low-nanomolar-range concentrations. Moreover, when administered *in vivo* to mice with CIA at low-nanogram doses, the SE mimetic significantly facilitated arthritis onset, increased the incidence and severity of the disease, and enhanced OC-mediated erosive bone damage. These findings substantiate the SE ligand hypothesis. Moreover, given the known structure–function properties and receptor-binding characteristics of the *c*(HS4-4) agonist, the knowledge acquired in this study could lay the foundation for future design of SE antagonists as a novel class of therapeutic agents in RA.

Materials and Methods

Reagents, cells, and mice

Ficoll-Paque PLUS was purchased from GE Healthcare (Piscataway, NJ). 2',7'-Dichlorodihydrofluorescein was purchased from Invitrogen (Carlsbad, CA). Murine M-CSF and receptor activator for NF- κ B ligand (RANKL) were obtained from PeproTech (Rocky Hill, NJ). Denatured chicken collagen type II (CII) was purchased from Chondrex (Redmond, WA). CFA containing *Mycobacterium tuberculosis* H37Ra was obtained from BD Difco (Franklin Lakes, NJ). Alexa Fluor 647 anti-mouse CD4 (clone GK1.5), FITC anti-mouse CD3 (clone 17A2), PE-conjugated anti-mouse IL-17A mAb (clone TC11-18H 10.1), and their corresponding isotype controls were purchased from BioLegend (San Diego, CA). All other commercial reagents were bought from Sigma-Aldrich (St Louis, MO).

Synthetic peptides corresponding to position 65–79 on the HLA-DR β -chain, coded by the SE-positive allele *DRB1*04:01*, designated in this article as 65–79*0401 (sequence: 65-KDLLLQKRAAVDTYC-79), were synthesized and purified (>90%) as we previously described (12). The 5-mer linear peptide 70–74*0401 (carrying the 70-QKRAA-74 sequence) was synthesized by the University of Michigan (Ann Arbor, MI) peptide synthesis core. The *c*(HS4-4) compound is a backbone cyclic mimetic peptide, synthesized as explained earlier (11). Recombinant mouse CRT was purified as described (6).

The mouse OC precursor cell line RAW 264.7 was purchased from American Type Culture Collection (Manassas, VA) and cultured as described (10). Human PBMCs were isolated from healthy blood donors as previously explained (13). Procedures involving human subjects were conducted under an institutional review board–approved protocol.

DBA/1 mice, 6 to 10 wk old, were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were maintained and housed at the University of Michigan Unit for Laboratory Animal Medicine facility, and all experiments were performed in accordance with protocols approved by University of Michigan Committee on Use and Care of Animals.

Surface plasmon resonance

Receptor–ligand interactions were determined using surface plasmon resonance (SPR) assays, as previously described (6–8). All assays were performed at 25°C in a binding buffer containing 10 mM HEPES, pH 7.4; 50 mM KCl; 0.5 mM CaCl₂; 100 μ M ZnCl₂; and 0.005% surfactant P-20. The immobilized level of mouse CRT was 3000 response units. The analyte was injected at a flow rate of 10 μ l/min.

Measurement of ROS

Production of reactive oxygen species (ROS) was determined as previously described (6, 12), using the ROS probe CM-H₂DCFDA. The fluorescence level was recorded every 5 min over a period of 500 min, using a Fusion α -HT system (PerkinElmer Life Sciences) at an excitation wavelength of 488 nm and emission wavelength of 515 nm. ROS levels are shown as fluorescence units per minute.

In vitro assay for OC differentiation

Murine OCs were generated from primary bone marrow (BM) cells isolated from femurs and tibias, as previously described (14, 15). Briefly, BM cells

were cultured in 48-well plates (2 \times 10⁵ cells per well) in α -MEM medium supplemented with 10% FBS, 100 U/ml penicillin, and 100 μ g/ml streptomycin, in the presence of 10 ng/ml M-CSF alone during the first 2 d, followed by 4 additional days in the presence of 10 ng/ml M-CSF, plus 20 ng/ml RANKL. Human OCs were differentiated from PBMCs isolated from healthy blood donors, as previously described (13). PBMCs were cultured for 7 d in 100 ng/ml M-CSF and 100 ng/ml RANKL supplemented in 10% FBS α -MEM. To quantify the number of OCs, cultures were fixed and stained for tartrate-resistant acid phosphatase (TRAP) activity using an acid phosphatase kit (Kamiya Biomedical Company, Seattle, WA) according to the manufacturer's instructions. TRAP-positive multinucleated OCs (more than three nuclei) were counted using a tissue culture inverted microscope.

In vitro bone degradation assays

Degradation of osteoblast-derived bone matrix was quantified as previously described (16), with some modifications. Briefly, 12,000 osteosarcoma cells (SaOS-2) per well were cultured in McCoy's 5A medium supplemented with 15% FBS in 48-well polystyrene culture plates. When cultures reached 80–90% confluence, the medium was changed to osteoblast differentiation medium (Life Technologies), containing 10% FBS, 2 mM glutamine, 300 mM ascorbic acid, and 10 mM β -glycerol phosphate. After 20–25 d, osteoblasts were removed using 15 mM NH₄OH. Mouse BM cells (200,000 cells per well in 48-well plates) were plated on the matrix in an OC differentiation medium, as above. After 15 d in culture, cells were removed using 15 mM NH₄OH, and matrix was stained with von Kossa dye. Photographs of individual wells were taken using a transmitted light microscope, and matrix abundance was quantified by ImageJ software.

To determine *ex vivo* bone degradation, 5-mm-diameter bovine cortical bone disks were prepared and studied as described, with some modifications (17). Disks were washed and sonicated in distilled water, and stored dry at room temperature. Before use, bone disks were sterilized by immersion in ethanol and placed under UV light for 30 min. Single disks were placed in individual wells of 48-well culture plates with 0.5 ml α -MEM + 10 ng/ml M-CSF + 20 ng/ml RANKL. Mouse BM cells, 400,000 cells per well, were incubated for 10 d, with replenishment of fresh media every other day. At the end of incubation, bone disks were removed and stained for TRAP, and the number of OCs per disk was determined as above. Cells and debris were then removed by two bursts of 15-s sonication in concentrated NH₄OH. Disks were stained with 1% toluidine blue for 30 s, and resorption pits were counted by scanning the entire surface of each disk with a reflected light microscope.

CIA induction and *in vivo* compound administration

DBA/1 mice (7 wk old) were immunized with chicken CII in CFA, as previously described (10). In brief, 50 μ l of an emulsion containing 100 μ g CII in 25 μ l 0.05 M acetic acid and 25 μ l CFA was injected intradermally at the base of the tail. Mice were injected once per week *i.p.* with *c*(HS4-4) at one of the following doses: 0.0, 0.8, 8, or 80 ng/gm body weight (BW), in 50 μ l PBS. Arthritis severity was determined as previously described (18), using a visual scoring system on a 4-point scale for each paw: 0 = no arthritis, 1 = swelling and redness confined to digits, 2 = minor swelling and redness spreading from the digits to the distal paw, and 3 = major swelling and redness extending proximally from the paw.

To determine the effect of the compound on Th17 cell differentiation *in vivo*, DBA/1 mice were injected *s.c.* in the footpad with 100 μ g CII emulsified in CFA. The inocula contained 8 or 80 ng/gm BW of *c*(HS4-4) in 50 μ l PBS, or an equal volume of PBS alone. Animals were sacrificed 7 d after immunization. Draining lymph nodes (DLNs) were collected, and single-cell suspensions were prepared. Unfractionated lymph node cells were cultured with PMA, ionomycin, and brefeldin A for 6 h. Cells were stained with Alexa Fluor 647 anti-mouse CD4, FITC anti-mouse CD3, or isotype controls, followed by fixation and permeabilization using a Cytofix/Cytoperm Kit. After permeabilization, intracellular staining was performed using PE-conjugated anti-mouse IL-17A, and cells were analyzed by flow cytometry. The results were analyzed with the FlowJo (TreeStar, Ashland, OR) software.

Joint tissue studies

Limbs were dissected and decalcified in 10% EDTA for 14 d. After decalcification, the specimens were processed for paraffin embedding and serial sectioning. The histologic sections were deparaffinized, rehydrated and stained with H&E, or stained for TRAP activity using a commercial kit (Kamiya Biomedical Company, Seattle, WA). To determine OC abundance, TRAP-positive multinucleated cells were counted. Data represent mean \pm SEM of the total number of OCs in front and rear paws and knees.




FIGURE 1. Chemical structure and ligand properties of *c*(HS4-4). **(A)** The chemical structure of *c*(HS4-4), a backbone cyclic peptide analog containing the SE consensus motif QKRAA, was designed to induce a stable active conformation. A backbone cyclization methodology was used to keep the functional groups of the side chain residues intact. This feature ensures that all the functional groups in a peptide sequence are available for biologic activity. **(B)** RAW 264.7 pre-OC cells (3×10^4 per well) were plated in flat-bottom 96-well plates in the presence of various concentrations of *c*(HS4-4), and ROS production was measured over time. **(C)** SPR data showing binding interactions between recombinant CRT immobilized on a biosensor chip, and *c*(HS4-4), 15-mer linear SE peptide 65–79*0401, or a 5-mer linear peptide 70–74*0401 (expressing the SE core sequence QKRAA), applied in the analyte. **(D)** A low-power docking image of the *c*(HS4-4) compound (identified here in its sequence structure cQKRAA and shown in green) superimposed onto the previously identified SE binding site on the CRT P-domain (gray surface). CRT amino acid residues previously found to play critical SE ligand-binding roles (7) are highlighted in red. **(E)** A high-power view of *c*(HS4-4)–CRT molecular interactions. For details see Table II.

Radiologic imaging

Bone damage was evaluated by radiography and micro-computerized tomography (micro-CT). Front and hind limbs from arthritic mice were dissected, fixed in 10% formalin, and stored in 70% ethanol. Limbs were scanned by a micro-CT system (eXplore Locus SP, GE Healthcare Pre-Clinical Imaging, London, ON) in distilled water. The protocol included the source powered at 80 kV and 80 μ A. In addition to a 0.508-mm Al filter, an acrylic beam flattener was used to reduce beam-hardening artifact (19). Exposure time was defined at 1600 ms per frame, with 400 views taken at increments of 0.5°. With four frames averaged and binning at 2×2 , the images were reconstructed with an 18- μ m isotropic voxel size. Regions of interest were defined through a spline-fitting algorithm to create separate masks for the carpals, tarsals, calcaneus, talus, or phalanges. The global threshold for cortical bone was defined at 2000 HU and 1200 HU for trabecular bone.

Radiographs were taken using a microradiography system (Faxitron X-Ray, Wheeling, IL) with the following operating settings: peak voltage,

27V; anode current, 25 mA; exposure time, 4.5 s. Coded radiographs were evaluated by an experienced rheumatologist who was blinded to the treatment. The presence of bone destruction was assessed separately for front and rear paws and scored on a scale of 0–5, ranging from no damage to complete destruction of the joints, as previously described (20).

Virtual ligand docking experiments

The compound *c*(HS4-4) was docked against a nuclear magnetic resonance-derived conformation of the CRT P-domain (Brookhaven Protein Data Bank ID: 1HHN), using the following two steps. First, the binding pocket was identified using the pipeline COACH (Ref. 21 and J. Yang, A. Roy, and Y. Zhang, manuscript in preparation). COACH is a consensus-based ligand binding site prediction approach that combines four template-based methods [COFACTOR (22), TM-SITE, S-SITE, and FINDSITE (23)] and ab initio method ConCavity (24). In the template-based approaches, sequence profile and structural comparisons are used to recognize the template proteins from the known function library BioLip (21), from which the ligand-binding information of the target is transferred; in the ab initio approach, the ligand binding site is derived from the cavity distribution on the surface of the target structures. A consensus binding pocket in the receptor structure was predicted by COACH, which is tethered by residues 216–225 and 255–260. The *c*(HS4-4) ligand was then docked onto the predicted binding pocket, using the ligand-docking software DOCK6 (25).

Statistical analysis

Data are expressed as mean \pm SEM. Unless stated otherwise, statistical analyses were performed using a two-tailed Student *t* test (**p* < 0.05, ***p* < 0.01, ****p* < 0.001).

Results

We have previously described 15-mer synthetic peptides carrying the SE sequence motif that acted as signal transduction ligands and activated pro-osteoclastogenic and proarthritogenic events (6, 10, 12). Because linear peptides are conformationally and biochemically unstable, the efficiency of linear SE peptides as signal transduction ligands was found to be rather low. To address this limitation, we have synthesized and screened a library of small (<1000 Da) backbone cyclic analogs, all containing a core SE sequence, QKRAA (11). The structural formula of the compound studied in this article, designated *c*(HS4-4), is shown in Fig. 1A. This 969-Da molecule has been previously shown to activate NO signaling in low nanomolar concentrations and displayed remarkable resistance to trypsin/chymotrypsin degradation (11).

Similar to the 15-mer linear SE peptide, *c*(HS4-4) activated ROS signaling in the pre-OC cell line RAW 264.7 (Fig. 1B) and bound to the SE receptor CRT in SPR experiments, albeit at a much higher affinity (Fig. 1C). As can be seen, when interacted with a SPR chip-immobilized CRT, *c*(HS4-4) produced a much higher SPR signal than the linear 15-mer SE ligand 65–79*0401, or the linear 5-mer peptide 70–74*0401, carrying the SE core sequence QKRAA. Kinetic analyses revealed that *c*(HS4-4) had a 10- to 100-fold higher affinity (lower K_D) to CRT compared with the linear peptides (Table I). As could be expected from its higher affinity, *c*(HS4-4) demonstrated potent signal transduction activities with 100- to 10,000-fold lower EC_{50} values, compared with the linear 15-mer SE ligand 65–79*0401 (Table I).

With use of the linear 15-mer SE ligand 65–79*0401, the binding site has been previously mapped to the region 217–224 of

Table I. Relative potencies of SE ligands

| SE Ligand | Affinity to CRT | | | EC_{50} (M) | |
|------------------|---------------------------|------------------------------|------------------------------|----------------------|----------------------|
| | K_a (1/Ms) | K_d (1/s) | K_D (M) | NO | ROS |
| <i>c</i> (HS4-4) | $2.7 \pm 0.5 \times 10^3$ | $1.4 \pm 0.2 \times 10^{-3}$ | $5.1 \pm 0.2 \times 10^{-7}$ | 1.0×10^{-9} | 4.5×10^{-9} |
| 70–74*0401 | $2.9 \pm 2.9 \times 10^2$ | $5.6 \pm 5.1 \times 10^{-3}$ | $9.5 \pm 7.6 \times 10^{-5}$ | ND | ND |
| 65–79*0401 | $5.1 \pm 4.8 \times 10^4$ | $7.4 \pm 3.1 \times 10^{-3}$ | $1.3 \pm 0.6 \times 10^{-6}$ | 6.0×10^{-5} | 4.5×10^{-7} |

Table II. Molecular interactions between *c*(HS4-4) and CRT

| <i>c</i> (HS4-4) Component | Interacting CRT Residue | Distance (Å) | Type of Interaction |
|----------------------------|-------------------------|--------------------|---------------------|
| HS4-4 Ring | Glu ^{223a} | <4.0 | Proximity |
| | His ²²⁴ | <4.0 | Proximity |
| | K | Asp ²²⁰ | 3.3 |
| R | | 3.8 | Electrostatic |
| | Asp ²⁰⁹ | 3.0 | Electrostatic |
| | Glu ²⁵⁷ | 3.0 | Electrostatic |
| | Trp ²⁵⁸ | 3.9 | Electrostatic |
| | | 3.9 | Electrostatic |
| A | None | N/A | N/A |
| | Asp ²²⁰ | 2.1 | H bond |

^aCRT residues are shown in a three-letter format.
^b*c*(HS4-4) amino acid residues are shown in a single-letter format.
 N/A, Not applicable.

the CRT P-domain (7). To determine the likelihood that *c*(HS4-4) interacts with that binding site as well, we have taken a virtual docking strategy. With the COACH algorithm (Ref. 21 and J. Yang, A. Roy, and Y. Zhang, manuscript in preparation), a binding pocket that overlaps with our previously mapped SE binding site (7) was identified in residues 216–225 of the CRT P-domain. The *c*(HS4-4) ligand was then docked onto that binding pocket, using the DOCK6 (25) software. As can be seen in Fig. 1D and 1E,

c(HS4-4) interacts with the same binding site as the linear SE ligand, particularly with 3 CRT residues that have been previously identified as playing a role in SE–CRT interaction (7). The molecular interactions between individual CRT residues and *c*(HS4-4) are displayed in Table II. Thus, taken together, our findings indicate that compound *c*(HS4-4) is a bona fide SE mimetic that potently interacts with the SE receptor CRT and activates signal transduction effects at low-nanomolar concentrations.

We have recently demonstrated that the 15-mer peptide SE ligand 65–79*0401 can activate osteoclastogenesis (10). Given the strong SE ligand properties of *c*(HS4-4), we have sought to determine whether it could activate osteoclastogenesis as well. To that end, BM cells derived from DBA/1 mice were cultured in an OC-differentiating medium, as previously described (10), in the presence of different concentrations of *c*(HS4-4) or PBS. After 6 d, cells were stained for TRAP, and OCs were counted. As seen in Fig. 2A, *c*(HS4-4) markedly enhanced OC differentiation in a dose-dependent manner ($EC_{50} = 3.3 \times 10^{-9}$ M). The *c*(HS4-4) facilitated OC differentiation in healthy human PBMCs as well ($EC_{50} = 4.5 \times 10^{-10}$ M). These potencies are ~100,000- and 1,000,000-fold higher than those of the linear 65–79*0401 15-mer peptidic SE ligand in the two respective cell systems (10). The osteoclastogenic effect of *c*(HS4-4) was accompanied by higher capacity to degrade artificial bone matrix and bovine bone disks *ex vivo* (Fig. 2B). In addition, similar to the immune dysregulatory




FIGURE 2. Functional activity of *c*(HS4-4). (A) BM cells harvested from DBA/1 mice (upper panel) or human PBMCs (lower panel) were cultured in triplicate with M-CSF and RANKL in the presence of various concentrations of *c*(HS4-4) or PBS, and TRAP-positive multinucleated cells were counted. Representative microscopic fields from cells treated with PBS or 100 nM *c*(HS4-4) are shown on the right upper and lower panels. (B) *c*(HS4-4) facilitates bone degradation *in vitro*. Primary DBA/1 mouse BM cells were cultured in triplicate with M-CSF and RANKL atop bone matrices (left panel) or bone slices (middle and right panels) in the presence of PBS, 58 μM of the SE ligand 65–79*0401, or 100 nM of *c*(HS4-4) in 48-well culture plates. Left panel, Matrix degradation was quantified on day 15 by digital scanning of tissue culture wells. Black areas represent intact matrix; white areas correspond to matrix degradation. Middle panel, BM cell cultures atop bone slices were stained for TRAP, and OCs were counted. Representative OCs are identified by the arrow, and their enlarged image is shown in the box in the left upper corner. Right panel, Bone slice–attached OCs were removed, and wells were stained with toluidine blue (TB). Bone pits are shown as black dots. Horizontal bars in all photos correspond to 100 μm. Bar graphs in the bottom represent mean ± SEM events from quintuplicate cultures in each of the three respective panels. (C) *c*(HS4-4) facilitates Th17 polarization. Mice were injected with CII/CFA, together with either 8 or 80 ng/gm BW of *c*(HS4-4) or PBS, as detailed in Materials and Methods. Abundance of CD4⁺ IL-17⁺ cells in DLNs was determined on day 7 by flow cytometry. Left, Images display representative dot plots. Right, Bar graphs display mean ± SEM of data obtained from six DLNs (three mice) in each group. All flow cytometry data were determined in duplicate samples from each DLN. White numbers within the black bars represent the administered dose (ng/gm BW) of *c*(HS4-4). Scale bars, 100 μm. **p* < 0.05, ***p* < 0.01, ****p* < 0.001.

effect of the linear 65–79*0401 15-mer peptidic SE ligand (9, 10), compound *c*(HS4-4) facilitated Th17 polarization (Fig. 2C). Thus, *c*(HS4-4) is a highly potent SE ligand that reproduces the entire spectrum of the previously identified SE immune dysregulatory and OC activation effects.

We next addressed the impact of *c*(HS4-4) on arthritis, using the CIA mouse model. CII-immunized DBA/1 mice were injected i.p. once a week with different doses of *c*(HS4-4) or PBS. As can be seen in Fig. 3, at doses of 80 and 800 ng/gm BW per week, *c*(HS4-4) significantly facilitated disease onset and increased disease incidence. Moreover, at a 80 ng/gm BW dose, but not in the higher dose, *c*(HS4-4) significantly increased mean arthritis scores, as determined by joint swelling. The swelling effect was more prominent in the early stage of the disease, yet was clearly significant throughout the duration of arthritis ($p = 1.8 \times 10^{-4}$, in a paired Student *t* test). The 0.8 and 8.0 ng/gm BW doses had no effect on any of the three CIA soft tissue disease parameters.

Radiologic analysis showed that irrespective of the effect of *c*(HS4-4) on tissue swelling, all mice treated with this compound had more severe erosive bone damage (Fig. 4A). To better quantify the bone effect of *c*(HS4-4), joints of mice treated with the two lowest concentrations were evaluated radiologically, using standard x-ray imaging. As can be seen in Fig. 4B, significantly greater bone damage occurred in mice treated with doses of *c*(HS4-4) that did not produce measurable effects on clinical scores of CIA.

Histologic examination of arthritic joints revealed significantly higher numbers of OCs in *c*(HS4-4)-treated mice, even at “sub-clinical” doses (Fig. 4C). The abundance of TRAP-positive mononuclear (pre-OC) cells was determined in the BM of all *c*(HS4-4)-treated mice (Fig. 5A) and showed a dose-dependent effect. Although the peak effect was seen in the 80 ng/gm BW treatment group, a statistically significant effect was seen in the group treated with a subclinical dose of 8 ng/gm BW as well. Upon ex vivo differentiation for 6 d, BM cells harvested from *c*(HS4-4)-




FIGURE 3. *c*(HS4-4) enhances arthritis. CIA mice were injected i.p. weekly with various doses of *c*(HS4-4) or PBS and monitored for CIA development. *Upper panel*, Mean day of arthritis onset. The *p* values were calculated using a two-tailed Student *t* test. *Middle panel*, Incidence curves. The *p* values were calculated using the log-rank (Mantel-Cox) test. *Lower panel*, Arthritis scores, shown as mean \pm SEM. The *p* values were calculated using a paired Student *t* test for the entire disease course ($n = 10$ per group).

treated CIA mice formed significantly higher numbers of OCs in a similar dose-dependent pattern (Fig. 5B).

Taken together, these results indicate that *c*(HS4-4), a potent peptidomimetic SE ligand, is highly arthritogenic. Although *c*(HS4-4) has a clear effect on joint swelling, it is a particularly potent facilitator of OC-dependent bone damage in inflammatory arthritis.





Discussion

We recently proposed an “SE ligand hypothesis,” which postulates that much of the impact of the SE on susceptibility to—and severity of—RA is attributable to signal transduction effects (26–28). In this study, we demonstrate that a small, biostable molecule mimicking the 70–74 core sequence motif of the SE is a highly potent ligand that binds to the SE receptor CRT, activates signal transduction, enhances OC functional activity in vitro, and facilitates arthritis and erosive bone damage in CIA. This small SE-mimetic compound reproduced the previously demonstrated (10) immune dysregulation, OC activation, and bone-destroying effects of a 15-mer linear peptide carrying the amino acid sequence of the region 65–79 on the HLA-DR β -chain, albeit at a much greater efficiency. These findings have two main implications: First, they shed important light on the biologic role of the SE and strongly support the SE ligand hypothesis; and second, they suggest that the new compound may be used in the future as a structural template for RA drug discovery.

The SE is the single most significant genetic risk factor for RA, but the mechanistic basis of its effect is unknown. Of interest, the SE not only confers a higher risk for RA but also increases the likelihood of developing more severe disease. For example, SE-coding *HLA-DRB1* alleles are associated with earlier disease onset and more severe bone erosions (29–32). Furthermore, there is evidence supporting gene-dose effect, whereby the severity of bone destruction in RA correlates positively with the number of SE-coding *HLA-DRB1* alleles (31, 32). The prevailing hypothesis over the past 20 y has postulated that the basis for SE-RA association is presentation of putative self or foreign arthritogenic Ags by SE-positive HLA-DR molecules (5). However, the identities of such target Ags remain unknown.

We have recently gained new mechanistic insights into the role of the SE in RA, by identifying it as a signal transduction ligand that binds to cell surface CRT and activates NO-mediated pro-oxidative signaling in a strictly allele-specific manner (6–8). In more recent studies, we have provided evidence directly implicating SE ligand effects in the pathogenesis of autoimmune arthritis, by demonstrating that a cell-free peptidic SE ligand facilitated in vitro and in vivo the differentiation of Th17 cells (9, 10) and OCs (10). Importantly, when administered to mice with CIA, the SE peptidic ligand increased joint swelling, synovial tissue OC abundance, and erosive bone damage (10).

In our ongoing efforts to examine the SE ligand hypothesis, in this study we applied a new level of ascertainment by examining a small, nonphysiologic synthetic compound. In its natural conformation within the HLA-DR molecule, the SE occupies ~ 1.5 α -helical loops in the third allelic hypervariable region of the HLA-DR β -chain (discussed in Ref. 28). On the basis of structural, functional, and evolutionary considerations, we have previously proposed that conformationally equivalent domains in many other MHC molecules are enriched in allele-specific signal transduction ligands that interact with non-MHC cell surface receptors and trigger signaling events. We further proposed that the SE ligand function is just a special case attesting to the broader theory (28). Our previous studies, which demonstrated that



a synthetic peptide carrying the SE linear sequence was proarthritogenic, were an important advancement toward substantiating the SE ligand hypothesis. However, owing to the random conformation of linear peptides in solution and their exquisite susceptibility to degradation, those studies required relatively high peptide concentrations. To address these limitations and examine the SE ligand in a format that more closely resembles its natural tridimensional conformation, we studied a backbone cyclic SE peptide.

As could be expected based on its biostability and predicted conformation (11), the SE-mimetic compound was found to be highly potent. It interacted with the SE receptor CRT at an affinity 10 times higher than that of the linear 15-mer SE peptide 65–79*0401 and 100 times higher than that of the linear 5-mer peptide 70–74*0401. Its signaling potency and pro-osteoclastogenic effect in vitro were found to be, respectively, 100,000- and 1,000,000-fold higher than those of 65–79*0401. Importantly, when administered in vivo to CIA mice, compound *c*(HS4-4) showed potent bone destructive effects at low-nanogram doses, a 250,000-fold higher potency than that seen with the linear 65–79*0401 SE peptide (10).




FIGURE 5. In vivo administered *c*(HS4-4) enhances BM osteoclastogenesis. (A) Fresh BM cells harvested from CIA mice treated with various doses of *c*(HS4-4) or PBS were analyzed by TRAP staining for the abundance of pre-OCs. (B) BM cells harvested from the same CIA mice were cultured for 6 d under OC-differentiating conditions, and OCs were quantified by counting multinucleated TRAP-positive cells. ****p* < 0.001.

Experiments involving in vivo administration of *c*(HS4-4) revealed an interesting differential effect in CIA. Although joint swelling was affected only by the higher *c*(HS4-4) dose range, bone destruction was observed at low concentrations as well, even in the absence of a visible impact on joint swelling. These findings suggest a mechanistic dichotomy between the effect of *c*(HS4-4) in these two aspects of arthritis. The molecular basis of this dichotomy requires additional study, but it is worth mentioning that discrepancies between joint swelling and bone destruction are not uncommon in RA. In some patients with a substantial DAS28, radiologic evidence of bone damage is minimal, despite RA chronicity; in other cases bone damage continues to progress despite quiescent synovitis. Mechanistic dissociation between inflammation and bone destruction pathways has been reported in experimental arthritis models in mice as well (20, 33). Evidently, much is to be learned about the interrelationship between synovitis and bone damage. The SE mimetic described in this article might be a useful experimental tool to dissect the molecular mechanisms underlying this discrepancy.

The rationale of using a backbone cyclization approach was based on our attempt to accomplish three goals. First, we wished to maintain the primary amino acid sequence intact. The advantage of the backbone cyclization methodology is its ability to prepare cyclic peptides without using the functional groups of the side chain residues. This feature is very important when functional groups in a peptide sequence are essential for biologic activity.

Second, we sought to preserve the native α -helical conformation of the SE. Third, we aimed to increase resistance to biodegradation. The high in vitro and in vivo potencies of *c*(HS4-4) are likely the end results of all the three design features. However, although biostability is likely attributable to the improved effects of *c*(HS4-4) in experiments involving in vitro or in vivo biologic milieus, resistance to enzymatic degradation probably had no impact on the higher receptor binding affinity of this compound, because receptor binding studies were carried out in a cell- and serum-free buffer space. Primary and secondary conformational factors, in contrast, were more likely responsible for the improved receptor affinity of compound *c*(HS4-4).

The apparent dependency of compound *c*(HS4-4) activity on its tridimensional structure is consistent with our previous observations, which suggested that the SE ligand is much more potent in its native α -helical conformation. In previous studies the SE ligand was shown to be effective in several different structural formats: 1) in its native conformation as part of cell surface SE-positive HLA-DR molecules, or as SE-expressing HLA-DR tetramers; 2) as cell-free non-HLA recombinant proteins genetically engineered to express the SE motif in its native α -helical conformation; or 3) as SE-positive short synthetic peptides. The SE ligand activated signaling in all formats; however, considerably lower concentrations of conformationally conserved reagents (e.g., tetramers or viral capsids expressing the SE sequence at the tips of α -helical spikes) were required to achieve signaling effects comparable to those achieved with linear, conformationally unstable SE peptidic ligands. Although formal structural analysis of *c*(HS4-4) has not yet been completed, its cyclic structure predicts that it may possess a helical conformation, thereby more closely resembling the native SE ligand (11).

The data presented in this article, along with the data we recently reported on a library of SE cyclic compounds with a range of biologic activities (11), provide for fairly detailed information based on structure and function that will help decipher the tridimensional characteristics of an “ideal” SE ligand. In addition, in other studies we have mapped the SE binding site on CRT (7) and determined the enhancing and inhibitory influences exerted on SE–CRT interaction by binding site neighboring amino acid residues (8). As the data shown in this article (Fig. 1D, 1E, Table II) demonstrate, high-resolution modeling of the tridimensional interactive relationships between the SE and its binding site is now achievable.

This study provides for the first time, to our knowledge, a structural framework to investigate disease-relevant tridimensional conformational parameters in SE–CRT interaction, and suggests that therapeutic targeting of this pathway deserves consideration. In this context, it should be pointed out that the use of global CRT antagonists might not be practical because CRT is a multifunctional protein. CRT has been shown to have many distinct binding sites that interact with other ligands, which, in turn, activate diverse functional activities (34). Consistent with this, *crt* gene knockout in mice leads to embryonic lethality (35), and knocking down *crt* gene expression in vivo by a short hairpin RNA approach did not produce a measurable impact on CIA in our hands, despite effectively suppressing *crt* expression levels (X. Pi and J. Holoshitz, unpublished observations). We therefore propose that selective targeting of SE–CRT interaction by site-specific inhibitors may be more effective than global anti-CRT approaches. The study presented in this article could lay the foundation for examining the utility of this strategy in the future.

Despite the advent of biologic agents, treating RA remains a challenging endeavor. The crux of the problem relates to a lack of sufficient understanding of the specific mechanisms that trigger

disease onset and affect disease severity. As a result, drug ineffectiveness and/or side effects are often encountered. The significance of the data presented in this article stems from the fact that they provide, for the first time, to our knowledge, well-defined structural parameters based on which small molecules with SE pathway inhibitory effects could be rationally designed in the future. Another potential future approach for drug discovery could involve high-throughput screening of libraries of small chemical compounds. Hits could be selected for further study based on their ability to compete with *c*(HS4-4) for CRT binding and to inhibit SE-activated signaling. Evidently, the design, identification, and testing of such drugs are all major endeavors. Time will tell if the structure–function properties of the SE-mimicking compound described in this article could be used in the design of future therapies.

Acknowledgments

We thank Gail Quaderer for administrative assistance.

Disclosures

S.L. and J.H. are named inventors on patents owned by the University of Michigan. The other authors have no financial conflicts of interest.

References

1. Gregersen, P. K., J. Silver, and R. J. Winchester. 1987. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. *Arthritis Rheum.* 30: 1205–1213.
2. Wucherpfennig, K. W., and J. L. Strominger. 1995. Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases. *J. Exp. Med.* 181: 1597–1601.
3. La Cava, A., J. L. Nelson, W. E. Ollier, A. MacGregor, E. C. Keystone, J. C. Thorne, J. F. Scavulli, C. C. Berry, D. A. Carson, and S. Albani. 1997. Genetic bias in immune responses to a cassette shared by different microorganisms in patients with rheumatoid arthritis. *J. Clin. Invest.* 100: 658–663.
4. Bhayani, H. R., and S. M. Hedrick. 1991. The role of polymorphic amino acids of the MHC molecule in the selection of the T cell repertoire. *J. Immunol.* 146: 1093–1098.
5. Klein, J., and A. Sato. 2000. The HLA system. Second of two parts. *N. Engl. J. Med.* 343: 782–786.
6. Ling, S., X. Pi, and J. Holoshitz. 2007. The rheumatoid arthritis shared epitope triggers innate immune signaling via cell surface calreticulin. *J. Immunol.* 179: 6359–6367.
7. Ling, S., A. Cheng, P. Pumpens, M. Michalak, and J. Holoshitz. 2010. Identification of the rheumatoid arthritis shared epitope binding site on calreticulin. *PLoS ONE* 5: e11703.
8. Ling, S., E. N. Cline, T. S. Haug, D. A. Fox, and J. Holoshitz. 2013. Citrullinated calreticulin potentiates rheumatoid arthritis shared epitope signaling. *Arthritis Rheum.* 65: 618–626.
9. De Almeida, D. E., S. Ling, X. Pi, A. M. Hartmann-Scruggs, P. Pumpens, and J. Holoshitz. 2010. Immune dysregulation by the rheumatoid arthritis shared epitope. *J. Immunol.* 185: 1927–1934.
10. Holoshitz, J., Y. Liu, J. Fu, J. Joseph, S. Ling, A. Colletta, P. Sharma, D. Begun, S. Goldstein, and R. Taichman. 2013. An HLA-DRB1-coded signal transduction ligand facilitates inflammatory arthritis: a new mechanism of autoimmunity. *J. Immunol.* 190: 48–57.
11. Naveh, S., Y. Tal-Gan, S. Ling, A. Hoffman, J. Holoshitz, and C. Gilon. 2012. Developing potent backbone cyclic peptides bearing the shared epitope sequence as rheumatoid arthritis drug-leads. *Bioorg. Med. Chem. Lett.* 22: 493–496.
12. Ling, S., A. Lai, O. Borschukova, P. Pumpens, and J. Holoshitz. 2006. Activation of nitric oxide signaling by the rheumatoid arthritis shared epitope. *Arthritis Rheum.* 54: 3423–3432.
13. Kim, J., Y. Jung, H. Sun, J. Joseph, A. Mishra, Y. Shiozawa, J. Wang, P. H. Krebsbach, and R. S. Taichman. 2012. Erythropoietin mediated bone formation is regulated by mTOR signaling. *J. Cell. Biochem.* 113: 220–228.
14. Kobayashi, K., N. Takahashi, E. Jimi, N. Udagawa, M. Takami, S. Kotake, N. Nakagawa, M. Kinoshita, K. Yamaguchi, N. Shima, et al. 2000. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. *J. Exp. Med.* 191: 275–286.
15. Koga, T., M. Inui, K. Inoue, S. Kim, A. Suematsu, E. Kobayashi, T. Iwata, H. Ohnishi, T. Matozaki, T. Kodama, et al. 2004. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. *Nature* 428: 758–763.
16. Lutter, A. H., U. Hempel, C. Wolf-Brandstetter, A. I. Garbe, C. Goettsch, L. C. Hofbauer, R. Jessberger, and P. Dieter. 2010. A novel resorption assay for osteoclast functionality based on an osteoblast-derived native extracellular matrix. *J. Cell. Biochem.* 109: 1025–1032.
17. Yang, C. R., J. H. Wang, S. L. Hsieh, S. M. Wang, T. L. Hsu, and W. W. Lin. 2004. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. *Cell Death Differ.* 11(Suppl 1): S97–S107.

18. Wooley, P. H., H. S. Luthra, J. M. Stuart, and C. S. David. 1981. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. *J. Exp. Med.* 154: 688–700.
19. Meganck, J. A., K. M. Kozloff, M. M. Thornton, S. M. Broski, and S. A. Goldstein. 2009. Beam hardening artifacts in micro-computed tomography scanning can be reduced by X-ray beam filtration and the resulting images can be used to accurately measure BMD. *Bone* 45: 1104–1116.
20. Joosten, L. A., M. M. Helsen, T. Saxne, F. A. van De Loo, D. Heinegard, and W. B. van Den Berg. 1999. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. *J. Immunol.* 163: 5049–5055.
21. Yang, J., A. Roy, and Y. Zhang. 2013. BioLiP: a semi-manually curated database for biologically relevant ligand-protein interactions. *Nucleic Acids Res.* 41(Database issue): D1096–D1103.
22. Roy, A., J. Yang, and Y. Zhang. 2012. COFACTOR: an accurate comparative algorithm for structure-based protein function annotation. *Nucleic Acids Res.* 40 (Web Server issue): W471–7.
23. Brylinski, M., and J. Skolnick. 2008. A threading-based method (FINDSITE) for ligand-binding site prediction and functional annotation. *Proc. Natl. Acad. Sci. USA* 105: 129–134.
24. Capra, J. A., R. A. Laskowski, J. M. Thornton, M. Singh, and T. A. Funkhouser. 2009. Predicting protein ligand binding sites by combining evolutionary sequence conservation and 3D structure. *PLOS Comput. Biol.* 5: e1000585.
25. Lang, P. T., S. R. Brozell, S. Mukherjee, E. F. Pettersen, E. C. Meng, V. Thomas, R. C. Rizzo, D. A. Case, T. L. James, and I. D. Kuntz. 2009. DOCK 6: combining techniques to model RNA-small molecule complexes. *RNA* 15: 1219–1230.
26. de Almeida, D. E., S. Ling, and J. Holoshitz. 2011. New insights into the functional role of the rheumatoid arthritis shared epitope. *FEBS Lett.* 585: 3619–3626.
27. Holoshitz, J., and S. Ling. 2007. Nitric oxide signaling triggered by the rheumatoid arthritis shared epitope: a new paradigm for MHC disease association? *Ann. N. Y. Acad. Sci.* 1110: 73–83.
28. de Almeida, D. E., and J. Holoshitz. 2011. MHC molecules in health and disease: at the cusp of a paradigm shift. *Self Nonself* 2: 43–48.
29. Gonzalez-Gay, M. A., C. Garcia-Porrua, and A. H. Hajeer. 2002. Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. *Semin. Arthritis Rheum.* 31: 355–360.
30. Mattey, D. L., A. B. Hassell, P. T. Dawes, N. T. Cheung, K. V. Poulton, W. Thomson, A. H. Hajeer, and W. E. Ollier. 2001. Independent association of rheumatoid factor and the HLA-DRB1 shared epitope with radiographic outcome in rheumatoid arthritis. *Arthritis Rheum.* 44: 1529–1533.
31. Plant, M. J., P. W. Jones, J. Saklatvala, W. E. Ollier, and P. T. Dawes. 1998. Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. *J. Rheumatol.* 25: 417–426.
32. Weyand, C. M., and J. J. Goronzy. 1994. Disease mechanisms in rheumatoid arthritis: gene dosage effect of HLA-DR haplotypes. *J. Lab. Clin. Med.* 124: 335–338.
33. Binder, N. B., A. Puchner, B. Niederreiter, S. Hayer, H. Leiss, S. Blüml, R. Kreindl, J. S. Smolen, and K. Redlich. 2013. Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis. *Arthritis Rheum.* 65: 608–617.
34. Gold, L. I., P. Eggleton, M. T. Sweetwyne, L. B. Van Duyn, M. R. Greives, S. M. Naylor, M. Michalak, and J. E. Murphy-Ullrich. 2010. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. *FASEB J.* 24: 665–683.
35. Mesaeli, N., K. Nakamura, E. Zvaritch, P. Dickie, E. Dziak, K. H. Krause, M. Opas, D. H. MacLennan, and M. Michalak. 1999. Calreticulin is essential for cardiac development. *J. Cell Biol.* 144: 857–868.